Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.

Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, Jochem-Kolb H.

Front Immunol. 2017 Jun 7;8:496. doi: 10.3389/fimmu.2017.00496. eCollection 2017. Review.

2.

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.

Heidenreich S, Kröger N.

Front Immunol. 2017 Feb 8;8:41. doi: 10.3389/fimmu.2017.00041. eCollection 2017. Review.

3.

Allelic Polymorphism Determines Surface Expression or Intracellular Retention of the Human NK Cell Receptor KIR2DL5A (CD158f).

Cisneros E, Estefanía E, Vilches C.

Front Immunol. 2017 Jan 17;7:698. doi: 10.3389/fimmu.2016.00698. eCollection 2016.

4.

Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing.

Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E, Jayaraman J, Wroblewski EE, Trowsdale J, Rajalingam R, Oksenberg JR, Chiaroni J, Guethlein LA, Traherne JA, Ronaghi M, Parham P.

Am J Hum Genet. 2016 Aug 4;99(2):375-91. doi: 10.1016/j.ajhg.2016.06.023.

5.

A vision of KIR variation at super resolution.

Hammond JA, Carrington M, Khakoo SI.

Immunology. 2016 Jul;148(3):249-52. doi: 10.1111/imm.12606. Epub 2016 Apr 5.

PMID:
26938992
6.

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.

Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J, Lim M.

J Immunol Res. 2016;2016:4683607. doi: 10.1155/2016/4683607. Epub 2016 Jan 4. Review.

7.

NK Cell Proliferation Induced by IL-15 Transpresentation Is Negatively Regulated by Inhibitory Receptors.

Anton OM, Vielkind S, Peterson ME, Tagaya Y, Long EO.

J Immunol. 2015 Nov 15;195(10):4810-21. doi: 10.4049/jimmunol.1500414. Epub 2015 Oct 9.

8.

Bone Marrow Cell Rejection, MHC, NK Cells, and Missing Self Recognition: Ain't That Peculiar (with Apologies to Marvin Gaye).

Raulet DH.

J Immunol. 2015 Oct 1;195(7):2923-5. doi: 10.4049/jimmunol.1501804. No abstract available.

9.

Co-evolution of MHC class I and variable NK cell receptors in placental mammals.

Guethlein LA, Norman PJ, Hilton HG, Parham P.

Immunol Rev. 2015 Sep;267(1):259-82. doi: 10.1111/imr.12326. Review.

10.

Inhibitory Receptors Beyond T Cell Exhaustion.

Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE.

Front Immunol. 2015 Jun 26;6:310. doi: 10.3389/fimmu.2015.00310. eCollection 2015. Review.

11.

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.

Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S.

Front Immunol. 2015 May 13;6:230. doi: 10.3389/fimmu.2015.00230. eCollection 2015. Review.

12.

Practical NK cell phenotyping and variability in healthy adults.

Angelo LS, Banerjee PP, Monaco-Shawver L, Rosen JB, Makedonas G, Forbes LR, Mace EM, Orange JS.

Immunol Res. 2015 Jul;62(3):341-56. doi: 10.1007/s12026-015-8664-y.

13.

The D0 Ig-like domain plays a central role in the stronger binding of KIR3DL2 to B27 free H chain dimers.

Hatano H, Shaw J, Marquardt K, Zhang Z, Gauthier L, Chanteux S, Rossi B, Li D, Mitchell J, Kollnberger S.

J Immunol. 2015 Feb 15;194(4):1591-601. doi: 10.4049/jimmunol.1402214. Epub 2015 Jan 12.

14.

Specific dysregulation of IFNγ production by natural killer cells confers susceptibility to viral infection.

Fodil N, Langlais D, Moussa P, Boivin GA, Di Pietrantonio T, Radovanovic I, Dumaine A, Blanchette M, Schurr E, Gros P, Vidal SM.

PLoS Pathog. 2014 Dec 4;10(12):e1004511. doi: 10.1371/journal.ppat.1004511. eCollection 2014 Dec.

15.

Natural killer cell regulation - beyond the receptors.

Watzl C, Urlaub D, Fasbender F, Claus M.

F1000Prime Rep. 2014 Oct 1;6:87. doi: 10.12703/P6-87. eCollection 2014. Review.

16.

Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Davies JO, Stringaris K, Barrett AJ, Rezvani K.

Cytotherapy. 2014 Nov;16(11):1453-66. doi: 10.1016/j.jcyt.2014.03.009. Epub 2014 May 20. Review.

17.

Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies.

Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, Bourhis JH, Spanholtz J.

Front Immunol. 2014 Mar 17;5:95. doi: 10.3389/fimmu.2014.00095. eCollection 2014. Review.

18.

Human NK cells: from surface receptors to the therapy of leukemias and solid tumors.

Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, Del Zotto G, Locatelli F, Moretta A, Mingari MC.

Front Immunol. 2014 Mar 7;5:87. doi: 10.3389/fimmu.2014.00087. eCollection 2014. Review.

19.

The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).

Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS.

Immunol Rev. 2014 Mar;258(1):45-63. doi: 10.1111/imr.12157. Review.

20.

Tumor-primed NK cells: waiting for the green light.

Sabry M, Lowdell MW.

Front Immunol. 2013 Nov 25;4:408. doi: 10.3389/fimmu.2013.00408. Review.

Supplemental Content

Support Center